Literature DB >> 1448405

Magnetic resonance imaging for the assessment of residual masses after treatment of non-Hodgkin's lymphomas.

C Montalbán1, J L Rodríguez-García, L Mazairas, I Ayala, J Marcos-Robles.   

Abstract

Eight patients with non-Hodgkin's lymphoma who were in clinical remission but showed residual masses after therapy were examined with magnetic resonance imaging at 1.5 T at the end of therapy, with the sequences TR/TE:500/35,500/70,2000/35 and 2000/70. Residual masses were found in lymphoid areas (7), spleen (3) and kidney (1). In three patients, T2 showed high signal intensity. Disease progressed in the following 1-3 months and active lymphoma was histologically identified. In the other five patients, T2 showed a very low signal intensity. One of them had a distant relapse in lymphoid areas but the remaining four patients are asymptomatic after a mean follow-up time of 13 months, suggesting that the lymphoma is cured and the mass inactive. We conclude that magnetic resonance imaging seems to distinguish active from non-active residual masses after treatment of non-Hodgkin's lymphoma patients otherwise in clinical remission.

Entities:  

Mesh:

Year:  1992        PMID: 1448405      PMCID: PMC2399570          DOI: 10.1136/pgmj.68.802.643

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  18 in total

1.  [The treatment of large-cell non-Hodgkin's lymphomas with the MACOP-B protocol].

Authors:  C Montalbán; J L Rodríguez García; J Marcos Robles; M Serrano; S Arechaga; J Perales; C Bellas
Journal:  Med Clin (Barc)       Date:  1991-10-26       Impact factor: 1.725

2.  Residual mediastinal masses in Hodgkin disease: prediction of size with MR imaging.

Authors:  R S Nyman; S M Rehn; B L Glimelius; H E Hagberg; A L Hemmingsson; C J Sundström
Journal:  Radiology       Date:  1989-02       Impact factor: 11.105

3.  Residual masses on follow-up computed tomography in patients with mediastinal non-Hodgkin's lymphoma.

Authors:  M Uematsu; M Kondo; T Tsutsui; T Murase; A Yorozu; H Hiramatsu; H Fujii; S Hashimoto
Journal:  Clin Radiol       Date:  1989-05       Impact factor: 2.350

4.  Lymphomas: MR imaging contrast characteristics with clinical-pathologic correlations.

Authors:  W G Negendank; A M al-Katib; C Karanes; M R Smith
Journal:  Radiology       Date:  1990-10       Impact factor: 11.105

5.  Post-therapy CT-detected mass in lymphoma patients: is it viable tissue?

Authors:  E Lewis; M E Bernardino; P G Salvador; F F Cabanillas; P A Barnes; J L Thomas
Journal:  J Comput Assist Tomogr       Date:  1982-08       Impact factor: 1.826

6.  High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma.

Authors:  N Peylan-Ramu; T B Haddy; E Jones; K Horvath; M A Adde; I T Magrath
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

7.  [Intraparenchymal non-neoplastic residual masses after treatment of large-cell non-Hodgkin's lymphoma with intensive chemotherapy].

Authors:  C Montalbán; S Arechaga; J L Calleja; C Bellas; J L Patier; A Berenguer; A García Villanueva; J Marcos Robles
Journal:  Med Clin (Barc)       Date:  1990-03-31       Impact factor: 1.725

8.  Non-Hodgkin lymphoma: predicting prognostic grade with MR imaging.

Authors:  S M Rehn; R S Nyman; B L Glimelius; H E Hagberg; J C Sundström
Journal:  Radiology       Date:  1990-07       Impact factor: 11.105

9.  Value of sonography in monitoring the therapeutic response of mediastinal lymphoma: comparison with chest radiography and CT.

Authors:  K Wernecke; P Vassallo; G Hoffmann; P E Peters; R Poetter; E Rummeny; P Koch
Journal:  AJR Am J Roentgenol       Date:  1991-02       Impact factor: 3.959

10.  Magnetic resonance imaging for assessment of treatment effects in mediastinal Hodgkin's disease.

Authors:  R Nyman; S Rehn; B Glimelius; H Hagberg; A Hemmingsson; B Jung
Journal:  Acta Radiol       Date:  1987 Mar-Apr       Impact factor: 1.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.